Chuangmei Pharmaceutical (02289) announced its interim results, and net profit of 22.556 million yuan increased 3.76% year over year

According to the Zhitong Finance App, Chuangmei Pharmaceutical (02289) announced interim results for the six months ended June 30, 2026. The group achieved operating income of 2,448 billion yuan, an increase of 13.6% year on year; net profit attributable to shareholders of the parent company was 225.56 million yuan, an increase of 3.76% year on year; basic and diluted earnings per share were 0.2088 yuan.

According to the announcement, the increase in revenue is mainly due to the continuous steady growth in domestic retail terminal drug demand, the continuous expansion of retail pharmacy channels, and the improvement of the overall market environment; the Group deepens brand cooperation: continues to implement the “deeply cultivate Guangdong and radiate the periphery” market strategy, further enhances recognition among brand manufacturers, obtains more high-quality product distribution rights and project cooperation opportunities, and continues to strengthen supply chain advantages. Continuously improving product supply chain satisfaction, optimizing supply chain service systems, and efficient and stable supply chain services are widely recognized by customers. Brand influence increased simultaneously, laying a solid foundation for the steady growth of the Group's main business.